The Efficacy of Voluven vs. Albumin Infusion in Prevention and Treatment of Clinical Vasospasm following Subarachnoid Hemorrhage

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Anesthesiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Resident, Department of Anesthesiology, School of Medicine And Student Research committee, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Department of Neurosurgery , School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Resident, Department of Internal Medicine, School of Medicine And Student Research committee, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Clinical vasospasm following subarachnoid hemorrhage is one of the most important causes of mortality during first two weeks after subarachnoid hemorrhage. Thus, some investigations have been conducted to evaluate the efficacy of triple-H accompanied with other drugs, such as calcium blocker, and early operation. In addition, colloid solutions such as albumin have also been used in treatment of hypervolemia. However, no study has compared different liquids. The aim of this study was to evaluate the efficacy of Voluven vs. albumin infusion (as hyper volume therapy) in prevention and treatment of clinical vasospasm following subarachnoid hemorrhage.Methods: This double-blind clinical trial that was performed in Alzahra Hospital, Isfahan, Iran, in 2011. We studied 64 patients with aneurysm, subarachnoid hemorrhage who referred to the hospital. The patients were divided into two groups. Early surgery was performed whenever possible and hypertensive hypervolemic hemodilution therapy was instituted with the first sign of clinical vasospasm. The first group was treated by albumin and the second group by Voluven liquids. Both groups were followed-up for 2 weeks. Glasgow Coma Scale (GCS) and Hunt-Hess Grade (HHG) were used for daily assessments of neurologic status, neurologic deficit, and hemodynamic status of the patients. Finally, the collected data was analyzed by SPSS.Findings: According to the results of this study, no statistically significant differences in the trend of GCS and HHG were observed between the two groups during follow-up (P > 0.05). Conclusion: There were not any significant differences between the two groups in terms of treatment results and complications. However, Voluven is cheaper than albumin. Therefore, Voluven can be efficiently used for prevention and treatment of clinical vasospasm following subarachnoid hemorrhage.

Keywords

References

  1. Hop JW, Rinkel GJ, Algra A, van GJ. Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Stroke 1997; 28(3): 660-4.
  2. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med 2000; 342(25): 1907-9.
  3. Fiwdlay MJ. Cerebral vasospasm. In: Winn HR, Youmans JR, editors. Youmans neurological surgery. 5th ed. Philadelphia: Saunders; 2004. p. 1839-67.
  4. Dorsch NW, King MT. A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage Part I: Incidence and effects. J Clin Neurosci 1994; 1(1): 19-26.
  5. Weir B, Grace M, Hansen J, Rothberg C. Time course of vasospasm in man. J Neurosurg 1978; 48(2): 173-8.
  6. Solomon RA, Onesti ST, Klebanoff L. Relationship between the timing of aneurysm surgery and the development of delayed cerebral ischemia. J Neurosurg 1991; 75(1): 56-61.
  7. Vermeij FH, Hasan D, Bijvoet HW, Avezaat CJ. Impact of medical treatment on the outcome of patients after aneurysmal subarachnoid hemorrhage. Stroke 1998; 29(5): 924-30.
  8. Levy ML, Giannotta SL. Cardiac performance indices during hypervolemic therapy for cerebral vasospasm. J Neurosurg 1991; 75(1): 27-31.
  9. Pritz MB. Treatment of cerebral vasospasm due to aneurysmal subarachnoid hemorrhage: Past, present, and future of hyperdynamic therapy. Neurosurg Quart 1997; 7: 273-85.
  10. Wood JH, Snyder LL, Simeone FA. Failure of intravascular volume expansion without hemodilution to elevate cortical blood flow in region of experimental focal ischemia. J Neurosurg 1982; 56(1): 80-91.
  11. Bailes JE, Spetzler RF, Hadley MN, Baldwin HZ. Management morbidity and mortality of poor-grade aneurysm patients. J Neurosurg 1990; 72(4): 559-66.
  12. Matsui T, Asano T. The hemodynamic effects of prolonged albumin administration in beagle dogs exposed to experimental subarachnoid hemorrhage. Neurosurgery 1993; 32(1): 79-83.
  13. Mayer SA, Solomon RA, Fink ME, Lennihan L, Stern L, Beckford A, et al. Effect of 5% albumin solution on sodium balance and blood volume after subarachnoid hemorrhage. Neurosurgery 1998; 42(4): 759-67.
  14. Treggiari MM, Walder B, Suter PM, Romand JA. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. J Neurosurg 2003; 98(5): 978-84.
  15. Gandhi SD, Weiskopf RB, Jungheinrich C, Koorn R, Miller D, Shangraw RE, et al. Volume replacement therapy during major orthopedic surgery using Voluven (hydroxyethyl starch 130/0.4) or hetastarch. Anesthesiology 2007; 106(6): 1120-7.
Journal of Isfahan Medical School
Volume 29, Issue 163 - Serial Number 163
September and October 2012
Pages 2018-2025

Files

History

  • Receive Date: 18 June 2011
  • Revise Date: 29 April 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics